Health Condition 1: I48- Atrial fibrillation and flutter Health Condition 2: I35- Nonrheumatic aortic valve disorders Health Condition 3: I34- Nonrheumatic mitral valve disorders Health Condition 4: Z952- Presence of prosthetic heart valve Health Condition 5: I080- Rheumatic disorders of both mitraland aortic valves
Conditions
Interventions
Intervention1: Magnesium sulphate along with standard practice: 2 grams MgSO4 in 100 ml normal saline administered over 10 min.
this is given as an adjunct to the standard of practice (SOP) for treat
Sponsors
Department of Emergency Medicine, AIIMS New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: Patients presenting to the emergency department with valvular atrial fibrillation with fast ventricular rate Age greater than or equal to 18 years Patients / Legally authorised representative willing to give valid consent
Exclusion criteria
Exclusion criteria: 1.Age below 18 years 2.Systolic blood pressure less than 90 mmHg 3.Atrial fibrillation associated with Wolff-Parkinson-White syndrome 4.Known chronic kidney disease with creatinine clearance below 30 ml/min 5.Presence of acute coronary syndrome 6.Pregnancy 7.Lack of consent from the patient 8.History of chronic malignancy 9.Known allergy to magnesium
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the proportion of successful rate control by intravenous magnesium sulphate along with standard practice as compared to standard practice alone in patients of valvular atrial fibrillationTimepoint: baseline and 12 hours | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To determine the proportion of successful rhythm control by intravenous magnesium sulphate along with standard practice as compared to standard practice alone in patients of valvular atrial fibrillation. 2. To determine the cumulative doses of AV nodal blocking agents required for rate control measure in patients with valvular atrial fibrillation receiving intravenous magnesium sulphate along with standard practice as compared to standard practice alone, until hospital discharge. 3. To determine the length of hospital stay in patients with valvular atrial fibrillation receiving intravenous magnesium sulphate along with standard practice as compared to standard practice alone. 4. To determine the safety outcomes of using intravenous magnesium sulphate in patients of valvular atrial fibrillation in terms of hypotension, use of vasopressors, patient reported flushing, non-invasive or mechanical ventilation & all-cause mortality until hospital dischargeTimepoint: baseline 12 hours 28 days | — |
Countries
India
Contacts
Public ContactSiddharth Sai Gunti Mohan
All India Institute of Medical Sciences, New Delhi
Outcome results
None listed